Bipolar Depression Market to Experience Notable Growth in Forecast Span, DelveInsight Predicts

DelveInsight's "Bipolar Depression Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Bipolar Depression, historical and forecasted epidemiology as well as the Bipolar Depression market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Bipolar Depression market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bipolar Depression Market Forecast
https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Bipolar Depression Market Report:
• The Bipolar Depression market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In January 2025, Autobahn Therapeutics, a biotech company focused on developing restorative therapies for neuropsychiatric and neuroimmunologic disorders, has initiated a Phase 2 clinical trial for ABX-002, a potent oral thyroid hormone beta receptor (TRβ) selective agonist, as an adjunctive treatment for bipolar depression in adults. This trial aims to establish both biological and clinical proof-of-concept, guiding the company's future clinical development strategy.
• In April 2024, NRx Pharmaceuticals announced encouraging results from its Phase IIb/III clinical trial comparing NRX-101 to lurasidone for treating suicidal bipolar depression. The findings showed a promising, though not yet statistically significant, 33% reduction in suicidality, along with a 70% reduction in akathisia symptoms (P=.076).
• In 2023, the United States held the largest market share among the 7MM for bipolar depression, with a market size of approximately USD 2,300 million, followed by Germany and Italy.
• By 2034, NRX-100 and NRX-101 are expected to secure a significant market share in the seven major markets (7MM).
• By 2034, CAPLYTA (lumateperone) is expected to hold the largest market share among existing therapies in the seven major markets (7MM).
• According to DelveInsight's estimates, there were approximately 3.6 million prevalent cases of bipolar depression in the 7MM in 2023, with severe cases making up the majority, around 75% of the total.
• According to DelveInsight's estimates, approximately 70% of the diagnosed prevalent cases of bipolar depression in 2023 were in the United States, out of the total cases in the 7MM.
• In 2023, severe cases made up the majority of bipolar depression diagnoses in the United States, accounting for around 75% of the total cases.
• In 2023, the United States had the highest number of treated bipolar depression cases among the 7MM, representing over 60% of the total treated cases.
• Key Bipolar Depression Companies: Allergan (AbbVie)/Gedeon Richter, Alkermes, Glaxo SmithKline (GSK), ELI Lilly and Company, Janssen Pharmaceuticals, Astellas Pharma Inc., Bristol Myers Squibb, Gedeon Richter Plc., H. Lundbeck A/S, Pfizer Inc., Novartis AG, Otsuka Holdings Co. Ltd, Validus Pharmaceuticals LLC, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), COMPASS Pathways, SAGE Therapeutics, Forest Laboratories, Target Health Inc., Vanguard, Inc., AstraZeneca, Celon Pharma SA, Intra-Cellular Therapies, Inc., Arvid Carlsson Research AB, Solvay Pharmaceuticals, Shire, Intra-Cellular Therapies, Inc., and others
• Key Bipolar Depression Therapies: VRAYLAR (Cariprazine), LYBALVI (olanzapine, samidorphan L-malate), NRX-100, NRX-101, SEP-4199, COMP 360 (Psilocybin Therapy), Sage-217, cariprazine, Ketamine Hydrochloride, Lurasidone HCl, Quetiapine Fumarate (SEROQUEL), Esketamine, Lumateperone, Brexpiprazole, OSU6162, Bifeprunox, carbamazepine ER, ITI-007 (Lumateperone), Olanzapine Fluoxetine Combination (OFC), lamotrigine, FK949E, SM-13496, and others
• The number of cases of each type of bipolar depression in the US in 2021 was 934.9K for bipolar depression I and 1445.9K for bipolar depression II, respectively
• The Bipolar Depression market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bipolar Depression pipeline products will significantly revolutionize the Bipolar Depression market dynamics.

Bipolar Depression Overview
A mental illness known as bipolar disorder (BD) is characterised by mood swings between mania and depression. Bipolar disorder (BD) is primarily divided into BD-I, BD-II, cyclothymic disorder, and bipolar disorder not otherwise specified (NOS) based on the characteristics of the episodes.

Get a Free sample for the Bipolar Depression Market Report:
https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Bipolar Depression Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Bipolar Depression Epidemiology Segmentation:
The Bipolar Depression market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Bipolar Depression
• Prevalent Cases of Bipolar Depression by severity
• Gender-specific Prevalence of Bipolar Depression
• Diagnosed Cases of Episodic and Chronic Bipolar Depression

Download the report to understand which factors are driving Bipolar Depression epidemiology trends @ Bipolar Depression Epidemiology Forecast
https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Bipolar Depression Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bipolar Depression market or expected to get launched during the study period. The analysis covers Bipolar Depression market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market :
The report also covers the Bipolar Depression Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Bipolar Depression Therapies and Key Companies
• VRAYLAR (Cariprazine): Allergan (AbbVie)/Gedeon Richter
• LYBALVI (olanzapine, samidorphan L-malate): Alkermes
• NRX-100/ NRX-101: NeuroRx
• SEP-4199: Sunovion (Sumitomo Dainippon Pharma)
• COMP 360 (Psilocybin Therapy): COMPASS Pathways
• Sage-217: SAGE Therapeutics
• cariprazine: Forest Laboratories
• Ketamine Hydrochloride: Target Health Inc.
• Lurasidone HCl: Vanguard, Inc.
• Quetiapine Fumarate (SEROQUEL): AstraZeneca
• Esketamine: Celon Pharma SA
• Lumateperone: Intra-Cellular Therapies, Inc.
• Brexpiprazole: Otsuka America Pharmaceutical
• OSU6162: Arvid Carlsson Research AB
• Bifeprunox: Solvay Pharmaceuticals
• carbamazepine ER: Shire
• ITI-007 (Lumateperone): Intra-Cellular Therapies, Inc.
• Olanzapine Fluoxetine Combination (OFC): Eli Lilly and Company
• lamotrigine: GlaxoSmithKline
• FK949E: Astellas Pharma Inc
• SM-13496: Sumitomo Pharma Co., Ltd.

Discover more about therapies set to grab major Bipolar Depression market share @ Bipolar Depression Treatment Market
https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Bipolar Depression Market Drivers
• Future Directions in Blood Biomarkers
• Increase in Awareness and Technology
• Advances Toward Precision Medicine for Bipolar Depression

Bipolar Depression Market Barriers
• Misdiagnosis of Bipolar Depression
• Unsatisfactory Design of RCTs
• Limited Understanding of the Disease Mechanism

Scope of the Bipolar Depression Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Bipolar Depression Companies: Allergan (AbbVie)/Gedeon Richter, Alkermes, GlaxoSmithKline (GSK), ELI Lilly and Company, Janssen Pharmaceuticals, Astellas Pharma Inc., Bristol Myers Squibb, Gedeon Richter Plc., H. Lundbeck A/S, Pfizer Inc., Novartis AG, Otsuka Holdings Co. Ltd, Validus Pharmaceuticals LLC, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), COMPASS Pathways, SAGE Therapeutics, Forest Laboratories, Target Health Inc., Vanguard, Inc., AstraZeneca, Celon Pharma SA, Intra-Cellular Therapies, Inc., Arvid Carlsson Research AB, Solvay Pharmaceuticals, Shire, Intra-Cellular Therapies, Inc., and others
• Key Bipolar Depression Therapies: VRAYLAR (Cariprazine), LYBALVI (olanzapine, samidorphan L-malate), NRX-100, NRX-101, SEP-4199, COMP 360 (Psilocybin Therapy), Sage-217, cariprazine, Ketamine Hydrochloride, Lurasidone HCl, Quetiapine Fumarate (SEROQUEL), Esketamine, Lumateperone, Brexpiprazole, OSU6162, Bifeprunox, carbamazepine ER, ITI-007 (Lumateperone), Olanzapine Fluoxetine Combination (OFC), lamotrigine, FK949E, SM-13496, and others
• Bipolar Depression Therapeutic Assessment: Bipolar Depression current marketed and Bipolar Depression emerging therapies
• Bipolar Depression Market Dynamics: Bipolar Depression market drivers and Bipolar Depression market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Bipolar Depression Unmet Needs, KOL's views, Analyst's views, Bipolar Depression Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.